BioSpace News Archive

Key factors driving the market such as increasing number of clinical trials worldwide and rise in adoption of outsourcing activities coupled with increasing R&D expenditures.

ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations.

The Wheelchair Market was valued at US$ 4,073.71 million in 2021 and is projected to reach US$ 6,459.07 million by 2028; it is expected to grow at a CAGR of 6.8% from 2021 to 2028.

More specifically, generated antibodies bind the RBD domains (responsible for binding human ACE2 receptors in human cells) of the Californian, South African, Brazilian and UK strains with the highest efficacy observed against the Delta variant (Indian).

The antiviral drug resistance market was valued at US$ 2,572.26 million in 2018 and it is projected to reach US$ 4,573.24 million in 2027; it is expected to grow at a CAGR of 6.8% from 2019 to 2027

Clover Biopharmaceuticals announced the completion of targeted enrollment of adult and elderly participants in SPECTRA, a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019, Clover’s COVID-19 vaccine candidate.

Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked.

The T-cell therapy market is anticipated to rise at a stellar growth rate for the forecast period between 2020 and 2030.

Retail clinics are the ones that provide primary healthcare services across departmental stores, supermarkets, and retail stores.

The preparative and process chromatography market is anticipated to display phenomenal growth rate over the forecast period from 2020 to 2030.